Skip navigation |

Poly-MVA - The First Dietary Supplement To Be Cleared By The FDA For Use In A Cancer Study

15 Jun 2008 Medical News Today-Original Article

CancerAssistanceCenter.org announces the immediate availability of free information packets for cancer patients and physicians regarding Poly-MVA, a dietary supplement that has been shown to be very effective in clinical studies conducted by a renowned board-certified oncologist, Dr. James Forsythe. When Poly-MVA (Palladium Lipoic Complex) was administered to terminally ill (Stage 4) cancer patients as an adjunct to the therapy they received during the 2005-2008 clinical studies completed by Dr. Forsythe, the Overall Survival Rate was 71% in the Poly-MVA group, an extraordinary result in view of the fact that less than 10% of those patients would have been expected to survive 2 years if they had continued to receive conventional therapy alone.

Dr. Forsythe's work was compelling and significant enough to convince the FDA to approve, for the first time in history, a cancer-related IND study (Investigational New Drug study) utilizing a dietary supplement. This FDA approved study has been designed to further validate the benefits of Poly-MVA for cancer patients. View Dr. Forsythe's Research on Poly-MVA here (PDF).

Poly-MVA was invented by Dr. Merrill Garnett, a biochemist. It is a dietary supplement based on the nontoxic lipoic acid-palladium complex (LAPd). LAPd is a liquid crystal that works in cancer cells by transferring excess electrons from membrane fatty acids to DNA via the mitochondria. It appears to be a safe and effective dietary supplement for cancer patients when used with or without conventional chemotherapy. Its safety profile is excellent and there were no treatment related deaths, significant adverse reactions or negative interactions with chemotherapy or hormonal treatments. The best responding tumors in Dr. Forsythe's studies were prostate cancer, breast cancer and lung cancer. Some of the remissions in Dr. Forsythe's studies involved brain cancer patients who had tried and failed conventional cancer treatment protocols. In addition to the remissions reported by Dr. Forsythe, there are other cancer remission case reports written by the patients themselves that can be found on the Foundation for Advancement in Cancer Research Web site: Cancer Survivors.

Is Poly-MVA the long waited solution for terminally ill cancer patients? Let's compare the facts. According to a report from the Journal of Clinical Oncology (2004) 16:549-560, the 5-Year Overall Survival Rate for Stage 4 cancer patients receiving chemotherapy treatments was 2.1%. In the clinical study conducted by Dr. Forsythe, 71% of the cancer patients in the Poly-MVA group were still alive and enjoying a good quality of life after 2 years. Additional articles on can be seen at: Cancer Articles.

''Will (the FDA) eventually re-categorize Poly-MVA as a drug? Quite possibly,'' said Dr. Frank Antonawich, Senior Scientist at Garnett McKeen Laboratory and Biology Dept. Chairman at St. Joseph's College in Patchogue, New York. "We've received an investigational new drug application from the FDA, and we're in the process of running tests…who knows, maybe in the future every physician will prescribe Poly-MVA as part of their patient's chemo and radiation package. That would be phenomenal too." -- St. Josephs College Magazine, February 2008, Vol. 6 No. 1 (Cancer Research).

Dr. Albert Sanchez, Founder of the Foundation for Advancement in Cancer Research, has been working with Poly-MVA ever since the supplement was first introduced 13 years ago. ''When Dr. Forsythe began his now famous clinical studies utilizing Poly-MVA for Stage 4 cancer patients who had failed conventional treatment, we had already been documenting one remission after another during the previous 9 years as one cancer patient after another realized the benefits of taking this extraordinary dietary supplement,'' said Dr. Sanchez. ''But we needed to move beyond purely anecdotal evidence in order to have a scientifically valid basis for bringing this news to the world. We now have that validation and I consider it my duty to shout the news from every mountain top.''

Foundation for Advancement in Cancer Research
www.facr.org